Procedural Rules
SR/Adhocsport/57/2019 IN THE MATTER OF PROCEEDINGS BROUGHT UNDER THE ANTI-DOPING RULES OF THE INTERNATIONAL ASSOCIATION OF ATHLETICS FEDERATIONS Before: Michael Beloff QC (Chair) Francisco A. Larios Jeffrey Benz BETWEEN: International Association of Athletics Federations (IAAF) Anti-Doping Organisation -and- Jarrion Lawson Respondent DECISION OF THE DISCIPLINARY TRIBUNAL A. INTRODUCTION 1. The Claimant, the International Association of Athletics Federations (“IAAF”), is the International Federation governing the sport of Athletics worldwide.1 It has its registered seat in Monaco. 2. The Respondent, Mr. Jarrion Lawson (the “Athlete”), is a 25-year-old American long jumper/sprinter. 3. On February 27, 2019, the Athletics Integrity Unit (“AIU”) charged the Athlete pursuant to Articles 2.1 and 2.2 of the IAAF Anti-Doping Rules (“ADR”) with an Anti-Doping Rule Violation (“ADRV’’) for the Presence and Use of a Prohibited Substance or its Metabolites or Markers, Epitrenbolone (a metabolite of Trenbolone). A. FACTUAL BACKGROUND 4. Below is a chronological summary of the undisputed evidence before the Disciplinary Tribunal (the “Tribunal”). 5. On April 11, 2018, the Athlete tested negative at a doping control test. 6. At all times between April 11, 2018 and June 2, 2018 he was subject to testing, during which period he competed on May 20, 2018 in the Seiko Golden Grand Prix Osaka 2018 in Osaka, Japan. 7. On June 2, 2018 in Springdale, Arkansas (USA), the Athlete underwent an Out-of- Competition doping control test following the Osaka meet. The Athlete provided a urine Sample with reference number 1609851 (the “Sample”). 8. On June 14, 2018, the A Sample was analysed by the WADA-accredited laboratory in Los Angeles, California (USA) (the “Laboratory”) and revealed the presence of Epitrenbolone (the “Adverse Analytical Finding” or “AAF”).
[Show full text]